Persistence of statin treatment – the impact of analytic method when estimating drug survival
DOI:
https://doi.org/10.5324/nje.v29i1-2.4052Sammendrag
Background: There is ample evidence for several pharmaceutical treatments that adherence in terms of
treatment duration and dose is suboptimal. The actual drug intake cannot be observed directly in prescription
databases, which only register drug redeemed and a limited number of patient characteristics. Consequently,
the actual dose and duration of treatment must be inferred from observed redemptions. Persistence can then
be expressed as treatment duration (also referred to as drug survival).
Method: We used data from the Norwegian Prescription Database (NorPD) on redemptions of statins (ATCcode
C10AA) for the period 2010-2019 to explore three methods for determining prescription durations and
in turn persistence (treatment duration): (i) The DDD-method using the number of DDD redeemed; (ii) The
dose-unit approach using the number of tablets redeemed; (iii) The reverse waiting time distribution method
(WTD), which estimates prescription duration as the 90th percentile of the distribution within which patients
in ongoing treatment will have a new subsequent redemption. The three methods for estimating prescription
duration were then used to estimate treatment duration using Kaplan Meier (KM) survival functions. For the
DDD-method and the dose-unit approach we conducted sensitivity analyses assuming that one DDD or one
tablet would last for 1.00, 1.25 or 2.00 days. We also tested the impact of grace periods in sensitivity analyses.
Results: Treatment duration and drug survival varied substantially for the same patients depending on the
chosen method, duration of a DDD or a tablet, and inclusion of grace periods. The 25th percentile of treatment
duration was 100 days for the DDD approach with one DDD per day, 100 days with the dose-unit approach
with one tablet per day and 453 days with the WTD approach.
Conclusion: When estimating treatment duration from prescription databases one should be aware that these
measures of persistence are highly influenced by the chosen methodology. The choice of method should be
informed by the clinical context with a preference for use of methods based on a formal model.
Downloads
Nedlastinger
Publisert
Hvordan referere
Utgave
Seksjon
Lisens
Opphavsrett 2021 Oteiza Francisco
Dette verket er lisensiert under en Creative Commons Attribution 4.0 International Lisens.
Norsk Epidemiologi licenses all content of the journal under a Creative Commons Attribution (CC-BY) licence. This means, among other things, that anyone is free to copy and distribute the content, as long as they give proper credit to the author(s) and the journal. For further information, see Creative Commons website for human readable or lawyer readable versions.
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
